News Quantified

AIM – aim immunotech inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event [Yahoo! Finance]

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

AIM ImmunoTech Announces Commencement of Rights Offering

Ascendiant Capital

Form 424B4 AIM ImmunoTech Inc.

Form EFFECT AIM ImmunoTech Inc.

Form S-1/A AIM ImmunoTech Inc.

Form 4 AIM ImmunoTech Inc. For: Feb 05 Filed by: CHEMEROW DAVID I.

Form 8-K AIM ImmunoTech Inc. For: Feb 05

Top News Gainers

3/9 AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 169.9%

9/24 Form S-1/A AIM ImmunoTech Inc. 48.2%

3/3 Form 424B5 AIM ImmunoTech Inc. 32.2%

2/11 AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus 26.2%

2/12 AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus 19.0%

9/19 AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer 18.9%

3/10 Form 424B5 AIM ImmunoTech Inc. 15.7%

12/2 Form 4 AIM ImmunoTech Inc. For: Nov 29 Filed by: EQUELS THOMAS K. 15.6%

11/1 Form 4 AIM ImmunoTech Inc. For: Oct 31 Filed by: APPELROUTH STEWART 13.8%

4/27 Form 8-K AIM ImmunoTech Inc. For: Apr 27 13.6%

Top News Decliners

9/25 Form S-1/A AIM ImmunoTech Inc. -44.1%

9/19 AIM Immunotech up 105% premarket after DOD grant for cancer study [Seeking Alpha] -32.3%

2/11 Form 8-K AIM ImmunoTech Inc. For: Feb 11 -28.4%

3/31 AIM ImmunoTech Reports 2019 Year-end Financial Results -24.9%

9/26 Form EFFECT AIM ImmunoTech Inc. -15.3%

2/18 Form 8-K AIM ImmunoTech Inc. For: Feb 18 -12.0%

9/24 Form 8-K AIM ImmunoTech Inc. For: Sep 19 -8.9%

4/6 AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic -8.1%

12/4 Form 8-K AIM ImmunoTech Inc. For: Dec 04 -7.9%

10/10 AIM ImmunoTech Inc. (NYSE: AIM) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. -7.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day